María del Pilar
Herrera Puente
Profesor/a Asociado/a en CC. de la Salud
Hospital Infanta Leonor
Madrid, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Infanta Leonor (9)
2024
-
COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant
Cancers, Vol. 16, Núm. 2
-
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851
2023
2021
-
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia
Cancer, Vol. 127, Núm. 12, pp. 2003-2014
-
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group
Leukemia and Lymphoma, Vol. 62, Núm. 12, pp. 2928-2938
-
Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 10, pp. e801-e809
2020
-
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study
Journal of Hematology and Oncology, Vol. 13, Núm. 1
2019
-
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia
Mediterranean Journal of Hematology and Infectious Diseases, Vol. 11
2014
-
Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: A bridge to individualized medicine
Clinical Lymphoma, Myeloma and Leukemia, Vol. 14, Núm. 4, pp. 305-318